New vaccine targets 24 pneumococcal strains in major trial
NCT ID NCT06678620
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a new 24-valent pneumococcal conjugate vaccine (PCV24) in 992 adults aged 18 and older. The study aims to check the vaccine's safety and how well it triggers an immune response compared to an existing 23-valent vaccine. Participants receive one dose of either PCV24 or the comparator vaccine, and researchers monitor side effects and antibody levels for 30 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
24-valent pneumococcal polysaccharide conjugate vaccine (PCV24)
What this could lead to
If successful, this could lead to a vaccine that protects against 24 types of pneumococcal bacteria, potentially preventing serious infections like pneumonia.
What could go wrong
This is an early phase II trial, so the vaccine may not trigger a strong enough immune response or could have unexpected side effects. Results may not apply to all populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIOUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pizhou Center for Disease Control and Prevention
Pizhou, Jiangsu, China
-
Xuzhou Center for Disease Control and Prevention
Xuzhou, Jiangsu, China